TY - JOUR
T1 - Breast-conserving surgery vs. total mastectomy in patients with triple negative breast cancer in early stages
T2 - A propensity score analysis
AU - De-La-Cruz-Ku, Gabriel
AU - Valcarcel, Bryan
AU - Morante, Zaida
AU - Möller, Mecker G.
AU - Lizandro, Sofia
AU - Rebaza, Lia P.
AU - Enriquez, Daniel
AU - Luque, Renato
AU - Luján-Peche, María G.
AU - Eyzaguirre-Sandoval, Miguel E.
AU - Saavedra, Antonella
AU - Razuri, Cesar
AU - Pinto, Joseph A.
AU - Fuentes, Hugo A.
AU - Neciosup, Silvia P.
AU - Gomez, Henry L.
N1 - Funding Information:
We thank to all the healthcare and administrative personnel of the National Institute of Neoplastic Diseases for supporting us in the development of this manuscript. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Publisher Copyright:
© 2020 IOS Press and the authors. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - BACKGROUND: Breast-conserving surgery (BCS) as an alternative to total mastectomy (TM) in patients with early-stage triple-negative breast cancer (TNBC) is not widely spread. OBJECTIVE: We aimed to compare the overall survival (OS) and disease-free survival (DFS) between both surgical approaches in early-stage TNBC patients at 10 years. METHODS: We conducted a retrospective cohort study in TNBC female patients with stage I-IIa, treated at a single-center during the period of 2000-2014. We estimated and compared the survival rates with the Kaplan Meier and Long-rank test. Propensity scores were calculated with the generalized boosted regression model and were used in the multivariate Cox regression analysis with the covariate adjustment method. RESULTS: We included 288 patients, 111 in the BCS vs. 177 in the TM group. The median follow-up was 102 months. Moreover, the patients in the BCS group had superior OS (85% vs. 81%, p = 0.56) and DFS (83% vs. 80%, p = 0.42) at 10 years. In the multivariate Cox analysis, BCS decreased the mortality risk (HR: 0.79, 95% CI: 0.37-1.67, p = 0.538), and the locoregional or distant recurrence risk (HR: 0.67, 95% CI: 0.32-1.41, p = 0.294), albeit with no statistical significance. CONCLUSION: BCS is a safe alternative to TM in Latin-American patients with early-stage TNBC.
AB - BACKGROUND: Breast-conserving surgery (BCS) as an alternative to total mastectomy (TM) in patients with early-stage triple-negative breast cancer (TNBC) is not widely spread. OBJECTIVE: We aimed to compare the overall survival (OS) and disease-free survival (DFS) between both surgical approaches in early-stage TNBC patients at 10 years. METHODS: We conducted a retrospective cohort study in TNBC female patients with stage I-IIa, treated at a single-center during the period of 2000-2014. We estimated and compared the survival rates with the Kaplan Meier and Long-rank test. Propensity scores were calculated with the generalized boosted regression model and were used in the multivariate Cox regression analysis with the covariate adjustment method. RESULTS: We included 288 patients, 111 in the BCS vs. 177 in the TM group. The median follow-up was 102 months. Moreover, the patients in the BCS group had superior OS (85% vs. 81%, p = 0.56) and DFS (83% vs. 80%, p = 0.42) at 10 years. In the multivariate Cox analysis, BCS decreased the mortality risk (HR: 0.79, 95% CI: 0.37-1.67, p = 0.538), and the locoregional or distant recurrence risk (HR: 0.67, 95% CI: 0.32-1.41, p = 0.294), albeit with no statistical significance. CONCLUSION: BCS is a safe alternative to TM in Latin-American patients with early-stage TNBC.
KW - Triple negative breast cancer neoplasm
KW - adjuvant chemotherapy
KW - breast-conserving surgery; overall survival
KW - distant disease-free survival
UR - http://www.scopus.com/inward/record.url?scp=85079780845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079780845&partnerID=8YFLogxK
U2 - 10.3233/BD-190391
DO - 10.3233/BD-190391
M3 - Article
C2 - 31903977
AN - SCOPUS:85079780845
VL - 39
SP - 29
EP - 35
JO - Breast Disease
JF - Breast Disease
SN - 0888-6008
IS - 1
ER -
